Focal Technology Area: Nanomedicines for Personalized
Headed by: Prof. Dan Peer
Advances in nano-scale science and
bio-nano-engineering are revolutionizing our understanding and ability to
manipulate complex biological processes, as well as the way health care is
administered. New approaches and innovations, collectively termed as
Nanomedicine, are on the verge of improving disease prevention, detection,
treatment and management.
The development of nanomedicines for theranostics
(therapy and diagnostics) of diseases is driven by principles from diverse
fields of science. Unlike conventional therapies
nanomedicines offer more effective treatment with reduced adverse effects by supporting:
Enhanced specificity in the delivery of large amounts of therapeutic or imaging payloads per recognition event;
Delivery of multiple agents simultaneously, and;
Overcoming biological barriers such as drug resistance.
In this project, we
develop new theranostics platforms. In particular we address cancer,
inflammation and cardiovascular diseases (all angiogenesis-dependent diseases)
focusing on enhanced personalization of the treatment
The Tel Aviv University FTA includes
nine principal investigators from Tel Aviv University and three principal
investigators from Ben-Gurion University of the Negev, The Hebrew University of
University. We are utilizing our members’ unique capabilities and developing
several strategies to target specific cell types in a personalized manner, i.e.
by sequencing patients'
designing specific nanocarriers with targeting agents appropriate to the
specific patient as well as designing personalized therapeutic payloads using
RNA interference (RNAi) strategy.
platforms are designed and synthesized from different biocompatible materials
(lipid based, soluble polymer based, dendrimers, inorganic nanoparticles
and polysaccharides based) with the ability to carry a variety of therapeutic
and imaging agents that can manipulate cellular functions with high specificity
and in a safe manner.
The consortium is
orchestrated by the director, Prof. Dan Peer, the vice director,
Prof. Ronit Satchi-Fainaro
and the technical manager,
Dr. Inbal Halevy
. Prof. Dan Peer is
coordinating the work by joint group meetings, scientific advisory board (SAB)
meetings headed by Prof. Robert Langer from MIT, annually and
intermediates scientific reports, through the website